Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC) linker platform.

The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...

Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject ...

Published in the peer-reviewed journal mAbs, the study presents nipocalimab's high-affinity binding to the neonatal Fc receptor (FcRn) and its capability to significantly reduce IgG levels ...

and PSMA), and cytokine moieties (e.g. CD16 genetic modifications to eliminate sensitivity to ADAM-17-mediated proteolytic cleavage or increase affinity for IgG Fc region have shown promising results.

A Precise and Powerful Mechanism Nipocalimab is a fully human monoclonal antibody that works by selectively binding to the neonatal Fc receptor (FcRn), disrupting the recycling of IgG antibodies.

IgY directed against conserved mammalian proteins is easier to produce than IgG because of the evolutionary distance between mammals and birds; and IgY does not bind to mammalian Fc receptors or ...

The shape of the IgE molecule differs dramatically from that of IgG. X-ray and nuclear magnetic ... high-affinity receptor FcεRI (high-affinity Fc receptor for IgE) on mast cells and antigen ...

S-1117 is a novel engineered Fc-fused pan-IgG protease targeting IgG autoantibodies, and S-4321 is a non-depleting bifunctional PD‑1: FcγRIIb‑selective agonist antibody for the treatment of ...

Proteintech has designed recombinant antibodies featuring the company's FcZero backbone, engineered to silence the Fc domain ...